Import from '@/components'

AOD-9604 After Acute Illness: When and How to Restart Safely

What Is AOD-9604 and Why Does Illness Change the Equation?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment (residues 176 to 191) of human growth hormone. It was originally developed by Metabolic Pharmaceuticals as an oral anti-obesity agent. The core hypothesis behind its use is that this fragment retains growth hormone's fat-metabolizing activity while avoiding the receptor-level signaling that drives GH's diabetogenic and growth-promoting effects.

Heffernan et al. (2001) demonstrated in rodent models that AOD-9604 stimulates lipolysis and inhibits lipogenesis through a mechanism that does not require GH-receptor activation. That finding is the single most-cited basis for its current off-label compounding use. The study was not conducted in humans, and it was not conducted in female-specific metabolic contexts.

Why Acute Illness Interrupts Peptide Protocols

Acute illness, whether a respiratory infection, gastrointestinal illness, urinary tract infection, or anything else that triggers systemic inflammation, produces a predictable set of hormonal shifts. Cortisol rises sharply. Insulin sensitivity drops. The growth hormone axis is suppressed by inflammatory cytokines, particularly interleukin-6 and tumor necrosis factor-alpha. Appetite and gastrointestinal motility change.

Each of those shifts interacts with the proposed mechanism of AOD-9604. A peptide that works through lipolytic pathways is being administered into a metabolic environment that is already under significant stress. Continuing the peptide through illness does not produce any known clinical benefit, and the theoretical risks, including additional metabolic strain during immune activation, are enough reason to pause.

No randomized controlled trial has specifically examined what happens when AOD-9604 is continued through acute illness. The guidance in this article is based on the underlying pharmacology, extrapolation from GH-axis physiology, and standard compounding-clinic practice.

The Specific Problem for Women

Women's GH secretion already differs from men's at baseline. Women secrete GH in higher pulse amplitude and with greater frequency across reproductive years, driven partly by estrogen's stimulatory effect on pituitary somatotrophs. Veldhuis et al. (1995) documented that estrogen amplifies GH pulse amplitude by approximately 2-fold in premenopausal women compared with age-matched men. That baseline difference matters when you are layering a GH-fragment peptide on top of an already-stressed axis.

During acute illness, estrogen levels may fluctuate. Fever and systemic inflammation can temporarily suppress hypothalamic function, blunting the LH pulse that drives estradiol production from the ovaries. Women who are already perimenopausal, and therefore already experiencing irregular estrogen surges and troughs, are operating with less hormonal buffer. Restarting AOD-9604 too quickly in this context adds a variable to an already-unstable axis.

How the GH Axis Behaves During and After Illness

Recovery from acute illness is not a clean on/off switch for the GH axis. The inflammatory response creates a period of relative GH resistance at the tissue level even after the pathogen or trigger has cleared.

Phase 1: Active Illness (Hold Entirely)

During active symptoms, IGF-1 levels drop because the liver, which produces IGF-1 in response to GH signaling, redirects resources toward acute-phase protein synthesis. This is a well-documented phenomenon: Van den Berghe et al. (2001) showed that critically ill patients have profound GH resistance, with low IGF-1 despite normal or elevated GH levels. The mechanism involves post-receptor signaling disruption by inflammatory mediators.

AOD-9604 is not GH itself, and it does not require GH-receptor activation. But its downstream lipolytic targets, including hormone-sensitive lipase and beta-adrenergic receptors on adipocytes, are also modulated by inflammation. Catecholamines released during acute illness already activate hormone-sensitive lipase. Adding AOD-9604 during this phase is redundant at best and metabolically new at worst.

Recommendation: Stop AOD-9604 at the first sign of systemic illness. Do not restart until you have been symptom-free for at least 5 days, and check with your prescribing clinician before doing so.

Phase 2: Early Recovery (Days 1 to 7 After Symptom Resolution)

The GH axis begins to normalize during early recovery, but inflammatory cytokines can remain elevated for 7 to 14 days after an acute infection resolves clinically. CRP, for example, may still be elevated even when you feel well. This sub-acute inflammatory state continues to suppress lipolytic signaling and may blunt any effect of AOD-9604.

Phase 3: Full Recovery (Day 7 to 14 and Beyond)

Most otherwise-healthy women are ready to consider restarting AOD-9604 between 7 and 14 days after their symptoms resolve, assuming no complications, no antibiotic course that is still ongoing, and no persistent systemic symptoms such as fatigue, night sweats beyond their baseline, or significant appetite disruption.

Women with chronic conditions, including PCOS, thyroid disease, or autoimmune conditions, warrant a longer recovery window. See the life-stage sections below.

A Practical Restart Framework for Women

The following restart framework is developed by the WomanRx clinical team based on compounding-practice norms, GH-axis physiology, and female-specific hormonal considerations. No RCT has validated this specific approach.

Step 1: Confirm full symptom resolution. You should be afebrile for at least 48 hours, off any prescribed antibiotics or antivirals, eating and sleeping at or near your baseline, and not experiencing significant fatigue. If you have any lingering symptoms, add 3 to 5 days before reassessing.

Step 2: Check your menstrual cycle status. If you are premenopausal and track your cycle, restart AOD-9604 at the beginning of the follicular phase (days 1 to 5 of your cycle). Estrogen is rising during this phase, which aligns with the most favorable GH-axis environment for lipolytic activity. Restarting mid-luteal phase, when progesterone is dominant and GH pulse amplitude is slightly lower, is not prohibited but may produce a less favorable initial response.

Step 3: Restart at 50 percent of your pre-illness dose for the first 5 days. If your protocol was 500 mcg daily, restart at 250 mcg for days 1 through 5. This gives your metabolic physiology time to re-acclimate without creating the kind of abrupt lipolytic signal that could cause nausea or injection-site reactions in a recently-stressed system.

Step 4: Return to your full dose on day 6 if tolerating well. Tolerating well means no new gastrointestinal symptoms, no significant injection-site reactions beyond normal, and no unexpected fatigue or mood changes.

Step 5: Notify your prescribing clinician. Any illness significant enough to warrant stopping AOD-9604 is significant enough to warrant a check-in with whoever prescribed it. They may want to assess your IGF-1 levels if the illness was prolonged, particularly if you experienced significant weight loss or muscle wasting during the acute period.

Life-Stage Considerations

Reproductive Years (Ages 18 to 40)

Women in their reproductive years are the most common users of AOD-9604 in the compounding context. Estrogen levels are generally adequate to support GH pulsatility, which means the axis has more capacity to recover after illness. The restart timeline of 7 to 14 days is appropriate for most women in this group.

The key variables are cycle phase (see Step 2 above), any underlying conditions like PCOS or endometriosis, and whether the illness required systemic treatment. A week-long course of fluoroquinolone antibiotics, for example, has known metabolic effects beyond infection control and warrants a more conservative restart timeline.

PCOS

Women with PCOS already have altered GH secretion. Morales et al. (1996) documented that women with PCOS have lower IGF-1 bioavailability relative to GH levels, suggesting a degree of GH resistance at baseline. Acute illness compounds this. After any illness requiring bed rest or significant dietary disruption, women with PCOS should use a 10 to 14-day minimum hold after symptom resolution before restarting AOD-9604, and they should restart at 50 percent dose for the full first week.

Insulin resistance, which is a hallmark of PCOS, worsens during acute illness and may take longer to return to an individual's baseline than systemic symptoms suggest. The lipolytic environment that AOD-9604 is intended to act in is still compromised even when you feel better.

Perimenopause (Roughly Ages 45 to 55, Variable)

Perimenopause produces dramatic and erratic fluctuations in estrogen and progesterone. GH pulse amplitude starts to decline in the late perimenopausal transition. Becker et al. (2012) documented that GH secretion declines significantly across the menopause transition, with the sharpest decline occurring in the two years surrounding the final menstrual period.

Acute illness in a perimenopausal woman lands on top of an already-declining GH axis. The result is a slower recovery of the endogenous hormonal environment that AOD-9604 is meant to work within. Perimenopausal women should use a minimum 10-day post-symptom hold and report any unusual patterns, such as worsening hot flashes, disrupted sleep, or new joint pain, to their clinician before restarting. These symptoms could reflect illness-triggered hormone shifts rather than a return to their pre-illness perimenopausal baseline.

Postmenopause

Postmenopausal women have persistently low estrogen, lower GH pulse amplitude, and higher visceral fat deposition, which is part of the reason peptide-based adipose strategies attract interest in this group. The GH axis is already less responsive, and the recovery from illness-related GH suppression may take longer. A 14-day minimum hold is reasonable in this group, with a dose reduction at restart and a longer titration back to full dose over 10 to 14 days.

What the Evidence Actually Shows (and Does Not Show)

AOD-9604's evidence base is thin by any clinical standard. The foundational data comes from animal studies. Heffernan et al. (2001) showed dose-dependent lipolysis stimulation in rodent fat tissue without GH-receptor-mediated growth effects. That is scientifically interesting and forms the rationale for human use, but it does not tell us about dosing in women, hormonal interactions, or illness recovery protocols.

The human trials conducted by Metabolic Pharmaceuticals in the early 2000s, including a Phase IIb study that enrolled participants with obesity, showed modest weight loss results and did not demonstrate statistically significant superiority to placebo at longer follow-up timepoints. These trials were summarized in the Australian Therapeutic Goods Administration evaluation (2004), which did not lead to approval. The trials were not powered or designed to examine sex-specific outcomes, post-illness protocols, or interactions with the menstrual cycle.

This is an honest evidence gap. Women have been historically underrepresented in metabolic peptide trials, and the post-illness restart question has never been formally studied in any population, male or female. Everything in this article that goes beyond the Heffernan animal data is extrapolation from GH-axis physiology, compounding-clinic experience, and the known biology of inflammation and recovery.

What We Can Say With Reasonable Confidence

• AOD-9604 does not activate the GH receptor, based on the Heffernan data, which distinguishes it from exogenous GH in terms of some risks.
• The lipolytic mechanism it is proposed to use depends on a metabolic environment that is disrupted during and after acute illness.
• Returning to full dose without a recovery period is unlikely to produce the intended effect and may cause unnecessary side effects during a period of systemic stress.

What We Cannot Say

• We cannot say that AOD-9604 is proven effective for fat loss in women at any dose.
• We cannot say that any specific restart interval is validated by trial data.
• We cannot say that continuing AOD-9604 through illness causes harm, because no study has examined this. The recommendation to stop is precautionary.

Pregnancy, Lactation, and Contraception

AOD-9604 is contraindicated in pregnancy and should not be used during breastfeeding.

There are no human pregnancy safety data for AOD-9604. No animal teratogenicity studies have been published in the peer-reviewed literature. The peptide modulates lipolysis and has structural homology to a portion of human growth hormone, which plays roles in placental development and fetal growth. ACOG's framework for evaluating investigational agents in pregnancy makes clear that the absence of safety data is not equivalent to a finding of safety.

If you become pregnant while taking AOD-9604, stop immediately and contact your prescribing clinician and obstetric provider.

For breastfeeding women, peptide transfer into breast milk is not characterized for AOD-9604 specifically. Until data exist, the conservative position is to avoid use entirely during lactation. Lipolytic activity during breastfeeding is a theoretical concern because the postpartum period already involves significant lipid mobilization and metabolic demands.

Contraception Requirements

AOD-9604 is not a teratogen with documented harm the way isotretinoin or valproate are. There is no mandated contraception program. But because the drug is unproven in pregnancy, any woman of reproductive potential using AOD-9604 should use reliable contraception if she is not trying to conceive, and she should stop the peptide as soon as a pregnancy is confirmed or suspected.

Women who are actively trying to conceive should discuss stopping AOD-9604 with their prescribing clinician before attempting conception. The ASRM's guidance on use of unproven therapies in fertility patients underlines the need for caution with any unvalidated compound during the preconception period.

Who This Protocol Is Right For (and Who Should Wait Longer)

Likely appropriate for the standard 7-to-14-day restart:

• Premenopausal women who had a self-limited illness (cold, mild flu, uncomplicated UTI) lasting fewer than 7 days
• No antibiotic course still in progress
• Eating and sleeping at baseline
• No underlying PCOS, thyroid disease, or active autoimmune condition

Use a longer hold (14 to 21 days minimum):

• Women with PCOS or thyroid disease (see ATA guidance on thyroid and infection)
• Perimenopausal or postmenopausal women
• Any illness requiring hospitalization or IV antibiotics
• Significant muscle loss or weight loss (more than 3 to 5 lbs) during illness
• Ongoing fatigue, brain fog, or appetite disruption beyond 7 days after symptom resolution

Do not restart without a clinician visit:

• COVID-19 or other illness with known post-acute sequelae risk
• Any illness that required systemic steroids (steroids substantially alter GH-axis function)
• Women who are or may be pregnant
• Women currently breastfeeding

Monitoring When You Restart

Your prescribing clinician may want to check baseline labs before you restart after a significant illness. Reasonable monitoring includes:

• Fasting glucose and insulin. Acute illness raises insulin resistance transiently, and confirming these have returned to your baseline is clinically relevant given AOD-9604's proposed mechanism in adipose tissue.
• CRP or ESR. Persistent elevation suggests ongoing inflammation that may blunt the peptide's intended effect and could indicate an incompletely resolved infection.
• IGF-1. Normal female reference ranges vary significantly by age and menopausal status, and a low IGF-1 after illness confirms GH-axis suppression that has not yet resolved. Restarting into a suppressed axis is not harmful by any known mechanism, but it may mean you are not yet in the physiological state where the peptide can work as intended.
• Thyroid function (TSH, free T4). Acute illness can unmask or worsen subclinical thyroid disease, particularly postpartum thyroiditis or Hashimoto's thyroiditis in women with pre-existing antibodies. Thyroid function significantly affects both GH secretion and lipolysis.

Your prescribing clinician should have a complete picture of your labs before you return to any peptide protocol after a significant illness.

Injection Technique After a Break

After 7 to 14 days without injecting, some women notice increased injection-site sensitivity. A few practical notes:

Rotate injection sites systematically. Subcutaneous sites in the abdomen, lateral thigh, and dorsal arm can all be used. Allow at least 2 cm between the current injection site and any site used in the previous 7 days.

Reconstituted peptide (in bacteriostatic water) that was stored properly during your illness hold, at 2 to 8 degrees Celsius and protected from light, remains stable for approximately 28 to 30 days after reconstitution according to standard compounding pharmacy labeling. If your illness extended beyond that window, you need a new vial. Do not use a peptide vial that has any cloudiness, particulate matter, or color change.

Administer on an empty stomach, ideally 30 to 60 minutes before your first meal or before morning exercise, which is the standard protocol for AOD-9604 in compounding practice. This timing aligns with the fasted-state lipolytic activity the peptide is theorized to support.